Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, SpainClara Mazagatos, Jacobo Mendioroz, Mercedes Rumayor et al.|Influenza and Other Respiratory Viruses|2024Cited by 25
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older EuropeansCharlotte Lanièce Delaunay, Carla López Causapé, Lisa Domegan et al.|JAMA Network Open|2024Cited by 10
Author response for "Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain"Clara Mazagatos, The SARI Sentinel Surveillance RSV Study Group, Jacobo Mendioroz et al.|Unknown|2024Cited by 0